Hikma Pharmaceuticals Appoints Former Teva Executive as CEO
Hikma Pharmaceuticals, an Amman, Jordan-based pharmaceutical company, has appointed Sigurdur Olafsson, a former executive at Teva Pharmaceutical Industries, as chief executive officer (CEO). Olafsson will also join Hikma’s Board of Directors as an executive director, subject to election at the company’s annual general meeting in May 2018. Said Darwazah, Hikma’s current chairman and CEO, will assume the position of executive chairman. These changes are effective immediately.
As CEO, Olafsson will be responsible for the development and execution of Hikma’s corporate strategy. All members of Hikma’s Executive Committee will report to Olafsson, who will report to Darwazah. He will initially be based in the US before relocating to Hikma’s head office in London.
As executive chairman, Darwazah will lead the Board of Directors. He will guide, oversee, and engage with the chief executive in setting and delivering the strategic vision for the company.
Olafsson was most recently president and CEO of the Global Generic Medicines Group of Teva Pharmaceuticals, a position he held from 2014 to 2016. From 2012 to 2014, he was president of Actavis, the generics business of Allergan. Prior to this, he was executive vice president, global generics, at Actavis from 2010 to 2012 and CEO of the Actavis Group from 2008 to 2010. From 2003 to 2008, he held positions of increasing responsibility within the Actavis Group, including deputy CEO, vice president of corporate development, and CEO of Actavis US. From 1998 to 2003, he held positions of increasing responsibility with Pfizer’s global research and development organization in the UK and US. From 1994 to 1998, he served as head of drug development for Omega Farma in Iceland. He currently serves as a member of the board of directors for Elucida Oncology, a clinical-stage biopharmaceutical company, and Pfenex, a biopharmaceutical company focused on non-glycosylated biosimilars.
Source: Hikma Pharmaceuticals